The OUtMATCH Study
Now Enrolling: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)
Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.
Watch a brief video about the study here.
Enrollment: This trial is active and currently enrolling.
How to Participate: For more information, call (404) 785-6448 to speak with a coordinator or email firstname.lastname@example.org
Who Can Participate: Anyone between the ages of 1-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.
- Age Range: 1-55 years
- Gender: Any
Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with individual study participation of up to 4 years and 8 months, but not past December 2023.
Study Location: Children’s Healthcare of Atlanta - Center for Advanced Pediatrics
Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Site Principal Investigator: Brian Vickery, MD
Study Coordinators: Ashley Dulson, Mary Vess and Randi Sylve
Study Primary Investigator: Robert Wood, MD
Co-Investigator(s): Meera Patrawala, MD and Tricia Lee, MD
Contact us: There are several ways to learn more about the study. You may reach us via one of the options below.
- Form: Complete the contact form below
- Email: email@example.com
- Phone: 404-785-6448
For additional information about our research program and the currently available clinical trials, visit our website here: Food Allergy Center @ Emory+Children's